Wave Life Sciences outlined key developments for 2026 at the J.P. Morgan Healthcare Conference.
Focus on accelerating WVE-007 for obesity treatment and advancing RNA editing portfolio.
Expectations include Phase 2a trials and new trials for WVE-007 with potential once or twice-yearly dosing.
Accelerating Development of WVE-007
Phase 2a multidose portion of WVE-007 trial for obesity expected to start in 1H 2026; new trials as add-on to incretin planned.
Positive Initial Data for WVE-007
240 mg single-dose data in 2025 showed improved body composition with fat loss similar to GLP-1 at three months; potential for once or twice-yearly dosing.
RNA Editing Portfolio Expansion
Success with WVE-006 for AATD; additional data updates for RestorAATion-2 in 2026; plans to file CTA for WVE-008 for homozygous liver disease.
- Wave's focus on RNA medicines and clinical advancements in obesity treatment are poised to bring transformative therapies.
- The positive initial data for WVE-007 and the expansion of the RNA editing portfolio showcase Wave's commitment to innovation and patient care.
Wave Life Sciences is well-positioned with strong clinical data and a clear development roadmap for 2026, demonstrating its potential for significant growth in the healthcare sector.